Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRINTELLIX vs AUVELITY
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Trintellix (vortioxetine) is a serotonin modulator and reuptake inhibitor. Its exact mechanism is not fully understood, but it is thought to work by inhibiting the reuptake of serotonin (5-HT) and by modulating several serotonin receptors, including 5-HT1A agonism, 5-HT1B partial agonism, 5-HT3 and 5-HT7 antagonism.
AUVELITY (dextromethorphan HBr and bupropion HCl) is an NMDA receptor antagonist (via dextromethorphan) and a norepinephrine-dopamine reuptake inhibitor (via bupropion). Dextromethorphan also modulates sigma-1 receptor activity.
Major Depressive Disorder (MDD) in adults
Major depressive disorder (MDD) in adults
10 mg orally once daily initially, then increase to 20 mg orally once daily based on tolerability; maximum 20 mg/day.
45 mg orally once daily, given as dextromethorphan hydrobromide 45 mg and bupropion hydrochloride 105 mg combination tablet.
Terminal elimination half-life is approximately 66 hours (range 58-78 hours) for vortioxetine. This supports once-daily dosing; steady-state is reached within 2-3 weeks.
Dextromethorphan: 13.5 hours (terminal half-life; prolonged due to CYP2D6 inhibition by bupropion, allowing sustained NMDA antagonism; bupropion: 13.7 hours)
Primarily metabolized by CYP2D6; minor pathways via CYP3A4/5, CYP2C9, CYP2C19, CYP2A6, CYP2B6, and CYP2C8. Primary metabolite is an inactive carboxylic acid metabolite.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (Cr Cl <15 m L/min).
e GFR 30-59 m L/min/1.73m2: 45 mg once daily; e GFR 15-29 m L/min/1.73m2: not recommended; e GFR <15 m L/min/1.73m2: contraindicated.
No dose adjustment for mild hepatic impairment (Child-Pugh A). For moderate impairment (Child-Pugh B): limit dose to 10 mg/day. Not recommended in severe impairment (Child-Pugh C).
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Trintellix is not approved for use in pediatric patients.
FDA Pregnancy Category C. First trimester: there is no adequate and well-controlled studies in pregnant women; based on animal data, there is potential risk of neural tube defects and cardiovascular malformations at doses lower than maximum recommended therapeutic dose. Second and third trimesters: exposure may increase risk of persistent pulmonary hypertension of the newborn (PPHN) and serotonin syndrome in the neonate if used near term; consider the risk of neonatal adaptation syndrome including respiratory distress, feeding difficulties, and irritability.
First trimester: No adequate studies; animal studies show no teratogenic effects at clinically relevant doses. Second and third trimesters: No reported fetal abnormalities; potential risk of neonatal serotonin syndrome if used near term due to SSRI component (dextromethorphan/bupropion). Avoid in third trimester unless benefit outweighs risk.
TRINTELLIX (vortioxetine) is an atypical antidepressant with multimodal activity: serotonin reuptake inhibition, 5-HT1A agonism, 5-HT1B partial agonism, and 5-HT3, 5-HT1D, and 5-HT7 antagonism. It has a favorable cognitive profile, particularly in processing speed and executive function, making it useful in elderly or cognitively impaired patients. Avoid in patients with uncontrolled seizure disorders or known bleeding risks (due to platelet serotonin depletion). Dosage adjustment required in CYP2D6 poor metabolizers or those taking strong CYP2D6 inhibitors (max dose 10 mg/day). Monitor for serotonin syndrome, especially when co-prescribed with other serotonergic agents.
Auvelity (dextromethorphan/bupropion) is a rapid-acting oral antidepressant approved for major depressive disorder. Onset of benefit may be seen within 1 week. It combines dextromethorphan (NMDA receptor antagonist/σ1 agonist) with bupropion (CYP2D6 inhibitor) to increase dextromethorphan exposure. Bupropion component also provides norepinephrine-dopamine reuptake inhibition. Avoid in patients with seizure disorders, eating disorders, or abrupt discontinuation of alcohol/benzodiazepines. Monitor for hypertension, suicidality, and serotonin syndrome. CYP2D6 poor metabolizers may have higher dextromethorphan levels; consider dose adjustment.
No interactions on record
No interactions on record
TRINTELLIX and AUVELITY are distinct pharmacological agents. TRINTELLIX belongs to the Antidepressant class and is primarily used for Major Depressive Disorder (MDD) in adults. AUVELITY belongs to the Antidepressant class and is primarily used for Major depressive disorder (MDD) in adults. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. TRINTELLIX carries a safety status of Category C, whereas AUVELITY safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Dextromethorphan is metabolized primarily by CYP2D6 to dextrorphan. Bupropion is extensively metabolized by CYP2B6 to hydroxybupropion, and to a lesser extent by CYP2C19, CYP2C9, and CYP3A4.
Primarily hepatic metabolism via CYP3A4 and CYP2C19, with approximately 26% of the dose recovered in urine (mostly as metabolites) and 60% in feces (mostly as metabolites). Less than 1% excreted as unchanged drug in urine.
Renal 81% (dextromethorphan and metabolites: 78% as unchanged drug and 3% as dextrorphan conjugates), fecal 9% (dextromethorphan and metabolites), biliary <1%
Approximately 98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Dextromethorphan: 60-70% bound to albumin; bupropion: 84% bound to albumin (highly protein bound; clinical significance minimal)
Apparent volume of distribution (Vd/F) is approximately 2600 L (or ~37 L/kg for a 70 kg person), indicating extensive tissue distribution.
Dextromethorphan: 5.3-6.4 L/kg (large Vd indicating extensive tissue distribution, crossing blood-brain barrier); bupropion: 20-25 L/kg (very large Vd due to lipophilicity and tissue binding)
Absolute bioavailability is approximately 75% for the oral tablet. Bioavailability is unaffected by food.
Oral: Dextromethorphan bioavailability is low (~3-5%) due to extensive first-pass metabolism; bupropion bioavailability is ~20% due to first-pass effect. Auvelity formulation (dextromethorphan + bupropion) increases dextromethorphan bioavailability via CYP2D6 inhibition
Child-Pugh Class A: no adjustment; Child-Pugh Class B: not recommended; Child-Pugh Class C: contraindicated.
Not FDA-approved for pediatric patients; no established dosing guidelines.
Not approved for use in pediatric patients. Safety and efficacy not established.
Initiate at 10 mg orally once daily; titrate cautiously. No specific dose adjustment other than careful monitoring.
No specific dose adjustment required. Monitor for increased sensitivity to anticholinergic effects (bupropion) and dissociative effects (dextromethorphan).
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS; AND NEUROPSYCHIATRIC REACTIONS. Antidepressants increased the risk of suicidal thoughts and behaviors in children, adolescents, and young adults. Bupropion is associated with neuropsychiatric reactions including mania, psychosis, and suicidal ideation in patients with bipolar disorder. Close monitoring is required.
Avoid alcohol. No specific food restrictions; taking with food may reduce nausea.
No specific food interactions have been reported. However, grapefruit juice may increase dextromethorphan levels via CYP3A4 inhibition, though clinical significance is unclear; caution advised. Avoid excessive caffeine intake as bupropion may increase caffeine levels and risk of seizures.
Excreted in breast milk in animals; not studied in humans. M/P ratio unknown. Caution recommended; benefit of breastfeeding should be weighed against potential risk of serotonin syndrome or other adverse effects in the infant. If used, monitor infant for drowsiness, fussiness, and poor feeding.
Excreted in human milk; M/P ratio not determined. Potential for serious adverse reactions in nursing infant, including serotonin syndrome. Decision to discontinue nursing or drug based on importance to mother. Use caution.
No formal dose adjustment recommended; however, pregnancy may decrease drug exposure due to increased volume of distribution and hepatic metabolism. Titrate to the lowest effective dose; monitor clinical response and adjust as needed. Avoid abrupt discontinuation due to risk of discontinuation syndrome.
Pregnancy may decrease bupropion exposure due to increased clearance; consider therapeutic drug monitoring and dose titration based on efficacy and tolerability. No specific dose adjustment data for Auvelity; use lowest effective dose.
Take once daily with or without food.,Do not stop abruptly; taper under medical supervision.,May cause nausea, which often resolves after 2 weeks; take with food to reduce nausea.,Avoid alcohol.,Report any unusual bleeding or bruising.,May take 2-4 weeks to see improvement; adherence is important.
Take one tablet once daily for 3 days, then increase to one tablet twice daily (at least 8 hours apart).,Swallow tablets whole; do not crush, chew, or divide.,Do not take with other bupropion-containing products or MAOIs.,May cause dizziness, headache, or insomnia; avoid driving until you know how it affects you.,Report new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior.,Avoid alcohol while taking this medication.,If you miss a dose, skip it and take the next dose at the scheduled time; do not double up.,Do not stop abruptly without consulting your healthcare provider.